Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Supplement 2 to Wave 1 Case Study Report 1:b:iii: Efalizumab Multi-Criteria Decision Analysis: Decision

First Page		Document Content
Date: 2014-07-16 01:09:14 Clinical research Immunosuppressants Science Efalizumab Autoimmune diseases Progressive multifocal leukoencephalopathy Psoriasis Placebo Clinical trial Medicine Health Pharmacology		Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Supplement 2 to Wave 1 Case Study Report 1:b:iii: Efalizumab Multi-Criteria Decision Analysis: Decision Add to Reading List Source URL: protectbenefitrisk.eu Download Document from Source Website File Size: 849,13 KB Share Document on Facebook

	Natürlich#gegen gelsen Spucke hilft! Der Speichel kann zwar keine Wunder vollbringen, doch die Wirkung geht über ein Placebo hinaus. DocID: 1v02o - View Document
	Placebo, control groups and the challenge of inferring causality Development team: Dr. Itay Asher and Dr. Iris Tabak, Ben Gurion University of the Negev; Israel; Samira Nasser, Beit Berl College, Israel; Lina Ganaim, Al- DocID: 1utvM - View Document
	Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura Marie Scully, Spero Cataland, Flora Peyvandi, Paul Coppo, DocID: 1utac - View Document
	ZX008 (Fenfluramine HCl Oral Solution) in Dravet Syndrome: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled TrialUniversity of Leuven, Leuven, Belgium; 2University of California, San Francisco S DocID: 1ubGU - View Document
	goal expectancies and placebo www.lekarzol.com DocID: 1u0V9 - View Document